Revenue up 20.7% but PBT swung to a US$1.6m loss as opex outran a 300bps...

What changed

Revenue rose 20.7% to US$67.7m from US$56.1m, with gross margin expanding roughly 300bps to 35.5% and gross profit stepping up to US$24.0m from US$18.2m. Despite that, operating profit swung from US$2.2m to a US$0.2m loss and PBT reversed from US$0.9m to a US$1.6m loss. Reported NPAT improved to -US$0.2m from -US$2.5m, but that is entirely a tax-line swing: FY24 carried a ~US$1.4m tax benefit against FY23's ~US$3.4m tax expense. Operating cash flow jumped 80% to US$11.7m, capex rose modestly to US$6.6m, and pre-lease free cash flow improved to US$5.1m from US$0.9m. Gross borrowings were paid down from US$25.7m to US$20.0m, but cash fell from US$12.7m to US$5.6m, so net debt still crept up to US$14.4m from US$13.0m. Inventories rose 11.1% to US$35.1m.

What matters

• PBT is the cleaner read, and it went the wrong way. A 20.7% revenue lift combined with a 300bps gross margin gain should have produced operating leverage; instead, costs below the gross line absorbed all of it and more. The headline 92% NPAT "improvement" is a tax-driven artefact and should not be read as operating progress.
• Cash conversion materially improved, but the cash balance still halved. OCF of US$11.7m and pre-lease FCF of US$5.1m are genuine step-ups. The US$7.1m cash drawdown is explained by the US$5.7m debt paydown plus capex, which tightens liquidity even as leverage nominally eases on the gross line.
• Extreme second-half weighting. HY24 delivered only 19.5% of full-year revenue (US$13.2m of US$67.7m), implying a US$54.5m H2. FY25 interim results will again look weak in isolation, so the read-through from any HY25 update will be limited.

Expectations

No quantified guidance, forward order book, or medium-term target was disclosed in the supplied excerpts, so the release cannot be assessed against management aspirations. The shape context confirms ArborGen's extreme H2-weighted planting-season pattern (roughly 80% of revenue in H2), but there is no disclosed basis to judge whether FY24's margin and cash-conversion improvement should extrapolate. The release supports a read of stronger top-line and cash generation, but does not support a read of improving bottom-line profitability.

Quality of result

Mixed. The gross margin expansion and the doubling-plus of pre-lease FCF look durable rather than timing-driven — inventory days actually eased slightly (to ~293 from ~304) even though inventory dollars rose, and receivables did not deteriorate. Against that, the PBT reversal indicates operating cost growth is outrunning revenue growth, and the NPAT line is flattered by a tax swing that is unlikely to repeat symmetrically. No full-year non-GAAP EBITDA reconciliation is provided in the FY24 excerpts, which limits ability to strip one-offs. Net debt edging higher despite strong OCF and lower gross borrowings shows the equity cash cushion, not the P&L, absorbed capex and financing outflows.

Unresolved

• What drove the step-up in costs below gross profit that turned a 300bps margin gain and a US$5.8m gross profit increase into a US$2.4m operating profit deterioration?
• What is the full-year adjusted US GAAP EBITDA that management typically cites, and how does it reconcile to the statutory operating loss?
• With cash at US$5.6m and US$1.2m of current debt, what is headroom on undrawn facilities and covenant position?
• Is the inventory build (+US$3.5m) aligned with booked FY25 orders, or is it speculative ahead of planting demand?
• No segment, customer concentration, or FX sensitivity disclosure is visible in the supplied extracts.

This briefing cannot assess valuation, covenant headroom, or forward demand, because NTA, facility terms, and order-book disclosures were not provided.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.